Publications by authors named "Laure Monard"
Objective: This study investigated the correlation between positive resection margins and outcomes in patients with pancreatic ductal adenocarcinoma who underwent surgery and adjuvant chemotherapy according to the pivotal trial PRODIGE 24-CCTG PA-6.
Background: The primary focus is on elucidating the prognostic significance of specific resection margins, including those associated with the superior-mesenteric vein (SMV), medial, and posterior pancreas.
Methods: The analysis involved 400 patients across multiple centers in France and Canada.
Article Synopsis
- GemPred is a predictive transcriptomic signature designed to assess the effectiveness of adjuvant gemcitabine in pancreatic cancer, validated through samples from 350 patients in a clinical trial comparing gemcitabine and mFOLFIRINOX treatments.* -
- Out of the patients studied, 25.5% were found to be GemPred+, showing significantly longer disease-free and cancer-specific survival when treated with gemcitabine compared to those who were GemPred-, but GemPred did not predict outcomes for those receiving mFOLFIRINOX.* -
- The study concludes that while GemPred+ patients experienced better survival rates with gemcitabine, they also suffered from more severe adverse events when treated with
Background: The REGOBONE multi-cohort study explored the efficacy and safety of regorafenib for patients with advanced bone sarcomas; this report details the Ewing sarcoma (ES) cohort.
Methods: Patients with relapsed ES progressing despite prior standard therapy, were randomised (2:1) to receive regorafenib or placebo. Patients on placebo could crossover to receive regorafenib after centrally confirmed progression.
Article Synopsis
- Scientists are working on a new way to help doctors find out if someone has colorectal cancer by testing a blood sample.
- They found three specific markers in the blood that are much higher in patients with advanced cancer than in healthy people.
- Their new method can help quickly spot cancer, which could make personalized treatments better for patients.
Importance: Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified FOLFIRINOX vs gemcitabine in patients with resected pancreatic ductal adenocarcinoma; mature data are now available.
Objective: To report 5-year outcomes and explore prognostic factors for overall survival.
Design, Setting, And Participants: This open-label, phase 3 randomized clinical trial was conducted at 77 hospitals in France and Canada and included patients aged 18 to 79 years with histologically confirmed pancreatic ductal adenocarcinoma who had undergone complete macroscopic (R0/R1) resection within 3 to 12 weeks before randomization.
Objective: The prognosis of pancreatic cancer after curative surgery is burdened by frequent recurrence. The aim of this study was to evaluate the impact of dysplasia in the surgical specimen on disease-free survival (DFS).
Methods: A post-hoc analysis of the phase III PRODIGE 24-CCTG PA 6 trial was performed.
Background: Although gemcitabine-based chemotherapy is the standard of care for advanced biliary tract cancers (BTCs), adjuvant phase III studies (BCAT in Japan, PRODIGE 12 in France) failed to show benefit, possibly owing to fewer patients (n = 225 and n = 194) compared with the adjuvant capecitabine BILCAP trial (n = 447). We performed a combined analysis of both gemcitabine-based chemotherapy adjuvant studies.
Methods: We performed individual patient data meta-analysis of all patients included in BCAT and PRODIGE 12.
Article Synopsis
- The study focused on analyzing relapse patterns in osteosarcoma patients from the OS2006/Sarcome-09 trial to inform future clinical trial designs.
- Out of 157 patients who relapsed after achieving initial complete remission, most relapses were metastatic, with a median time to relapse of 1.7 years; treatments often included systemic therapy and surgery.
- The findings suggest conducting randomized phase-II trials that accommodate all age groups and patients regardless of measurable disease status, prioritizing progression-free survival as the main endpoint.
Background: This multi-cohort trial explored the efficacy and safety of regorafenib for patients with advanced sarcomas of bone origin; this report details the cohort of patients with metastatic or locally advanced chondrosarcoma (CS), progressing after prior chemotherapy.
Patients And Methods: Patients with CS, progressing despite prior standard therapy, were randomised (2:1) to receive regorafenib or placebo. Patients on placebo could crossover to receive regorafenib after centrally confirmed progressive disease.
Oral Tocofersolan Corrects or Prevents Vitamin E Deficiency in Children With Chronic Cholestasis.
J Pediatr Gastroenterol Nutr
December 2016
Objectives: D-Alpha-tocopheryl polyethylene glycol 1000 succinate (Tocofersolan, Vedrop), has been developed in Europe to provide an orally bioavailable source of vitamin E in children with cholestasis. The aim was to analyze the safety/efficacy of Vedrop in a large group of children with chronic cholestasis.
Methods: Two hundred seventy-four children receiving Vedrop for vitamin E deficiency or for its prophylaxis were included from 7 European centers.